Valion Bio Expands Entolimod Platform for Oncology Growth
SAN ANTONIO, Texas, July 14, 2026 Valion Bio, Inc. has announced major strategic progress across its Entolimod platform, advancing...
Biodefense
Advertisement
RedHill Advances Opaganib as Potential Ebola Treatment Amid Rare Bundibugyo Virus Outbreak
TEL AVIV, Israel and RALEIGH, N.C., June 2, 2026 RedHill Biopharma has announced efforts to advance the clinical development...
Emergent BioSolutions Secures $64.5M U.S. Contract for BAT® Antitoxin
GAITHERSBURG, Md. | May 28, 2026 Emergent BioSolutions announced it has received a $64.5 million contract modification from the...
Soligenix Advances Bundibugyo Ebola Vaccine Platform
PRINCETON, New Jersey, May 26, 2026 Soligenix, Inc. has announced that its proprietary ThermoVax® vaccine platform may provide a...
HDT Bio Advances CCHF Vaccine Into Phase 1 Trial
Seattle, Washington, USA – May 21, 2026 HDT Bio and The University of Texas Medical Branch (UTMB) have received...
Advertisements
Tivic Advances Radiation Syndrome Therapy with NIAID
San Antonio, Texas, March 26, 2026 In a strategic move to address critical gaps in radiation emergency therapeutics, Tivic...
Emergent Secures $140M Canada Health Deal
WINNIPEG, Manitoba – February 26, 2026 Emergent BioSolutions (NYSE: EBS) has announced approximately $140 million CAD in multiyear contract...
Canada Awards $22.5M Mpox Vaccine Contract
COPENHAGEN, DENMARK — February 18, 2026 Bavarian Nordic has secured a USD 22.5 million vaccine supply contract from the...
GC Biopharma’s Recombinant Anthrax Vaccine Shows Strong Phase 2 Safety and Efficacy Results
Yongin, South Korea — November 3, 2025 GC Biopharma has announced promising Phase 2 clinical trial results for its...
FDA Clears HDT Bio’s First-in-Class Tick-Borne Disease Vaccine
SEATTLE, Sept. 19, 2025 – HDT Bio Corporation has announced that the U.S. Food and Drug Administration (FDA) has...
Advertisement
